J&J: positive data for anti-depressant nasal spray
(CercleFinance.com) - J&J reports that a study published in the New England Journal of Medicine found that patients receiving the Spravato nasal spray (esketamine) for treatment-resistant depression (TRD) were 1.
54 times more likely to achieve remission after eight weeks than those treated with extended-release quetiapine (XR).
They were also 1.55 times more likely not to relapse up to 32 weeks after achieving remission at week 8.
J&J says that Spravato is indicated, in combination with an oral antidepressant, to treat adults with TRD, and to treat depressive symptoms in adults with major depressive disorder (MDD), accompanied by suicidal thoughts or actions.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
54 times more likely to achieve remission after eight weeks than those treated with extended-release quetiapine (XR).
They were also 1.55 times more likely not to relapse up to 32 weeks after achieving remission at week 8.
J&J says that Spravato is indicated, in combination with an oral antidepressant, to treat adults with TRD, and to treat depressive symptoms in adults with major depressive disorder (MDD), accompanied by suicidal thoughts or actions.
Copyright (c) 2023 CercleFinance.com. All rights reserved.